AMRX
Amneal Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$19.36
+0.94%Year over year
Reported trailing growth
- Revenue
- +9.3%
- EBITDA
- +11.7%
- EBIT
- +7.2%
- EPS
- +4825.7%
- Free cash flow
- -68.3%
- Operating cash flow
- -42.8%
Forward estimates
Based on analyst estimates
- Revenue
- +5.9%
- EBITDA
- +41.4%
- EPS
- +118.4%
Three-year CAGR
- Revenue
- +10.9%
- EBITDA
- +11.1%
- EBIT
- +43.9%
- Net income
- +161.6%
- EPS
- +160.5%
- Free cash flow
- -1.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026